With reference to the subject cited, this is to inform the Exchange that the Board of Directors of Oxygenta Pharmaceutical Limited, at its Meeting held on Wednesday, 04th February, 2026, at 12:00 noon at the corporate office of the Company, considered and approved the following: 1. Un-audited Financial Results for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 2. Limited Review Report for the quarter and nine months ended 31.12.2025. (Attached as Annexure) 3. Re-constitution of Internal Complaints Committee (ICC) constituted under The Sexual Harassment of Women at Workplace (Prevention, Prohibition, and Redressal) Act, 2013 (POSH Act) w.e.f., 04.02.2026. (Attached as Annexure -I)